ReportsnReports - LIver Disease Treatments: The Global Market
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

ReportsnReports - LIver Disease Treatments: The Global Market

on

  • 441 views

CC's goal in conducting this study is to provide an overview of the current and potential aspects of the global market for liver diseases treatments market. The report determines the market size and ...

CC's goal in conducting this study is to provide an overview of the current and potential aspects of the global market for liver diseases treatments market. The report determines the market size and market leaders, provides a market overview, and examines factors affecting the markets for drugs used to treat liver diseases. The markets have been defined by disease type and by drug type.

Statistics

Views

Total Views
441
Views on SlideShare
441
Embed Views
0

Actions

Likes
0
Downloads
4
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

ReportsnReports - LIver Disease Treatments: The Global Market Document Transcript

  • 1. LIver Disease Treatments: The Global MarketReportsnReports.com adds BCC Research Market Research Report “LIver DiseaseTreatments: The Global Market’’ to its store.STUDY OBJECTIVESBCC’s goal in conducting this study is to provide an overview of the current and potentialaspects of the global market for liver diseases treatments market. The report determinesthe market size and market leaders, provides a market overview, and examines factorsaffecting the markets for drugs used to treat liver diseases. The markets have been definedby disease type and by drug type.The overview of types of liver diseases, their symptoms and their treatments is examinedalong with sales figures over the five-year period from 2009 to 2014. The report also givesthe demand and use criteria of the drugs used to treat liver diseases, as well as an overviewof drug-induced liver diseases. Companies manufacturing and selling the drug products inthis category are profiled, and factors affecting markets for these products and how themarkets are likely to change are analyzed. Revenues have been broken down by the type ofdiseases and by different regions.Our key objective is to present a comprehensive analysis of the current market and thefuture direction of the drugs used to treat liver diseases.REASONS FOR DOING THIS STUDYA large number of studies are currently ongoing regarding hepatitis and other liver diseases,which influenced BCC’s desire to study this market.This study looks at almost all of the types of products used to treat liver diseases, Theresearch and development of new products, and the changes in market behavior that justifyfocusing on this segment. Finally, this study discusses the usage of these products.INTENDED AUDIENCEThe study contributes to understanding market growth and decline in the market for liverdisease treatments, from the point of view of the manufacturer and user. This study will beof interest largely to the chemical, pharmaceutical and biopharmaceutical industries, as wellas clinics and hospitals.SCOPE OF THE STUDYThe scope of this study encompasses the market for liver disease treatments. BCC analyzeseach market and its leaders, the different types of liver diseases, the different types of drugproducts to treat liver diseases, the regulatory environment, the regional market for liverdiseases and the drug products used to treat them, and market projections and marketshare. Technological issues include latest trends and new developments.METHODOLOGYA combination of primary and secondary research methods were used in this study. A
  • 2. comprehensive search of literature was conducted. The literature included technicalnewsletters and journals as well as many other sources. The data were collected throughinterviews and correspondence with various pharmaceutical/ biotechnical experts.Projections were based on estimates such as the current number of end users, potential endusers, likely unit prices, rates of consumption, and market trends.INFORMATION SOURCESBCC surveyed many companies to obtain data for this study. Included were manufacturersand the end users of the drugs used to treat liver diseases. We gathered industry data,spoke with officials from this industry, and consulted newsletters, company literature,product literature, and a host of technical articles, journals, indexes, and abstracts.Exhaustive investigations of databases by key terminology were done. In addition, wecompiled data from current financial and trade information and government sources.ABOUT THE AUTHORShalini Shahani Dewan holds a Masters Degree in pharmaceutical chemistry. Among theresearch topics she has covered are studies on compounds of potential pharmaceuticalinterest from ibuprofen and 2-naphthyl acetic acid. Shahani was awarded a gold medal bythe Prime Minister of India for her work and has worked with top companies in India and inthe U.S. Some of her other reports with BCC are: Reagents of Chromatography;Spectroscopy, an Enduring Market; Advanced Drug Delivery Systems; Orthopedic Drugs,Implants and Devices; Imaging Reagents; Contract Manufacturing, Research andPackaging; The Dynamic Media, Sera and Reagent Market in Biotechnology; Opportunities inChiral Technology; Behavioral and Emotional Disorders in Children and Adolescents;Pharmaceutical Regulatory Industry,and many more.Table Of ContentsChapter- 1: INTRODUCTION – ComplimentarySTUDY OBJECTIVESREASONS FOR DOING THIS STUDYINTENDED AUDIENCESCOPE OF THE STUDYMETHODOLOGYINFORMATION SOURCESABOUT THE AUTHORRELATED REPORTSBCC ONLINE SERVICESDISCLAIMERChapter- 2: SUMMARYTable 0 : GLOBAL SALES OF LIVER DISEASE TREATMENTS, THROUGH 2014Figure 0 : GLOBAL SALES OF LIVER DISEASE TREATMENTS, 2007-2014Chapter- 3: OVERVIEWDEFINITIONSTHE LIVERChapter- 4: REGULATORY ISSUES
  • 3. Table 2 : APPROVED DRUGS USED TO TREAT LIVER DISEASES, 2005–2008Table 3 : NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVERDISEASES, 2005–2008Figure 1 : NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVERDISEASES, 2005–2008Table 4 : NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT LIVER DISEASES,2005–2008Table 5 : RECALLS OF DRUGS USED TO TREAT LIVER DISEASES, 2005–2008Chapter- 5: PREVALENCEUNITED STATESUNITED KINGDOMREST OF THE WORLDPREVALENCE OF A FEW LIVER DISEASESChapter- 6: CLASSIFICATION OF THERAPIES BY DISEASEVIRUS-INDUCED LIVER DISEASE/HEPATITISLIVER TUMORS/ LIVER CANCERCONGENITAL LIVER DEFECTSAUTOIMMUNE LIVER DISORDERSALCOHOL-INDUCED LIVER DISEASECHRONIC LIVER DISEASENON-ALCOHOLIC FATTY LIVERChapter- 7: INDUSTRY STRUCTUREHEPATITISLIVER TUMORSAUTOIMMUNE DISEASESALCOHOL-INDUCED LIVER DISEASESCHRONIC LIVER DISEASENON-ALCOHOLIC FATTY LIVER DISEASEChapter- 8: DEMAND AND USELIFE EXPECTANCYLACK OF KNOWLEDGELACK OF TREATMENT OPTIONSINCREASING NUMBER OF PATIENTSRESEARCH AND DEVELOPMENTINITIATIVES OF VARIOUS ORGANIZATIONS TO INCREASE AWARENESSChapter- 9: MARKET ANALYSISHEPATITISLIVER TUMORSAUTOIMMUNE DISEASESALCOHOL-INDUCED LIVER DISEASECHRONIC LIVER DISEASESNON-ALCOHOLIC FATTY LIVER DISEASE
  • 4. Chapter- 10: DRUG-INDUCED LIVER DISEASEDRUGS THAT CAN CAUSE LIVER DISEASEChapter- 11: NEW DEVELOPMENTSCLINICAL TRIALSNEW DEVELOPMENTSChapter- 12: MARKET BY DRUG TYPEMARKET SIZEMARKET SHAREVACCINESANTIVIRALSINTERFERONSIMMUNE GLOBULINSCHEMOTHERAPYTARGETED THERAPYCHELATING AGENTSCORTICOSTEROIDSIMMUNOSUPPRESSIVE AGENTSANTIMETABOLITESANABOLIC STEROIDSALCOHOL ABUSE DRUGSAnti-rejection MedicationINFECTION-FIGHTING DRUGSANTIFUNGAL PROPHYLAXISGALLSTONE SOLUBILIZING AGENTSOTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASESChapter- 13: PATENT ANALYSISPATENTS BY YEARPATENTS BY TYPEPATENTS BY COUNTRYPATENTS BY COMPANYPATENTS BY ASSIGNEETable 85 : NUMBER OF PATENTS BY ASIGNEE, 2005–2009Figure 52 : NUMBER OF PATENTS BY ASSIGNEE, 2005–2009Chapter- 14: COMPANY PROFILESABBOTT LABORATORIESACTAVIS U.S.ALKERMES, INCALNYLAM PHARMACEUTICALSBARR PHARMACEUTICALSBAYER SCHERING PHARMA AGBIOTEST PHARMACEUTICALS CORPORATIONBRISTOL-MYERS SQUIBBCANGENE CORPORATIONDEBIOPHARM GROUPELI LILLY & COMPANY
  • 5. FOREST LABORATORIES, INC.GALMED MEDICAL RESEARCH, LTD.GILEAD SCIENCES, INC.GLAXOSMITHKLINE PLCHUMAN GENOME SCIENCESIDENIX PHARMACEUTICALS INC.KINEMED, INC.MALLINCKRODTMEDA PHARMACEUTICALSMERCK & CO.NOVARTIS AGPAR PHARMACEUTICAL COMPANIES, INC.ROCHEROXANE LABORATORIES, INC.SANOFI AVENTISSAVIENT PHARMACEUTICALS, INC.SCHERING-PLOUGHSCYNEXISTALECRIS BIOTHERAPEUTICSTEVA PHARMACEUTICAL INDUSTRIES LTD.THREE RIVERS PHARMACEUTICALSUPSHER-SMITH LABORATORIESVALEANT PHARMACEUTICALS INTERNATIONALVERTEX PHARMACEUTICALS INCORPORATEDWATSON PHARMACEUTICALS, INC.WYETH INC.ZYDUS PHARMACEUTICALS INC.ZYMOGENETICSChapter- 15: APPENDIXAbbreviationsList of TablesSummary Table : GLOBAL SALES OF LIVER DISEASE TREATMENTS, THROUGH 2014Table 1 : TYPES OF LIVER DISEASESTable 2 : APPROVED DRUGS USED TO TREAT LIVER DISEASES, 2005–2008Table 3 : NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASES,2005–2008Table 4 : NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005–2008Table 5 : RECALLS OF DRUGS USED TO TREAT LIVER DISEASES, 2005–2008Table 6 : HEPATITIS BURDEN IN THE UNITED STATES (2005–2006)Table 7 : INCIDENCE OF ACUTE HEPATITIS BY SEX AND AGE IN THE UNITED STATES(2006)Table 8 : VACCINES FOR HEPATITIS A PREVENTIONTable 9 : VACCINES FOR HEPATITIS B PREVENTIONTable 10 : NUCLEOSIDE ANALOGS USED TO TREAT HEPATITISTable 11 : NUCLEOTIDE ANALOGS USED TO TREAT HEPATITISTable 12 : PROTEASE INHIBITORS USED TO TREAT HEPATITIS
  • 6. Table 13 : INTERFERONS USED TO TREAT HEPATITISTable 14 : IMMUNE GLOBULINS USED TO TREAT HEPATITISTable 15 : CHEMOTHERAPUTIC DRUGS USED TO TREAT LIVER CANCERTable 16 : TARGETED THERAPY USED TO TREAT LIVER CANCERTable 17 : DRUGS USED TO TREAT WILSON’S DISEASETable 18 : CORTICOSTEROIDS USED TO TREAT AUTOIMMUNE HEPATITISTable 19 : IMMUNOSUPPRESSIVE AGENTS USED TO TREAT AUTOIMMUNE HEPATITISTable 20 : ANTI-METABOLITES USED TO TREAT AUTOIMMUNE HEPATITISTable 21 : ANABOLIC STEROIDS USED TO TREAT ALCOHOLIC LIVER DAMAGETable 22 : ALCOHOL ABUSE DRUGS USED TO TREAT ALCOHOLIC LIVER DAMAGETable 23 : ANTI-REJECTION MEDICATIONSTable 24 : ANTI-INFECTIVESTable 25 : ANTIFUNGAL PROPHYLAXIS FOR LIVER TRANSPLANT RECIPIENTSTable 26 : GALLSTONE SOLUBILIZING AGENTS USED TO TREAT NON- ALCOHOLIC FATTYLIVER DISEASETable 27 : OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASETable 28 : HEPATITIS VACCINE: MARKET SHARE BY MANUFACTURER, 2008Table 29 : NUCLEOSIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BYMANUFACTURER, 2008Table 30 : NUCLEOTIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BYMANUFACTURER: 2008Table 31 : INTERFERONS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008Table 32 : IMMUNE GLOBULINS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER,2008Table 33 : CHEMOTHERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER,2008Table 34 : TARGETED THERAPY TO TREAT LIVER TUMORS: MARKET SHARE BYMANUFACTURER, 2008Table 35 : CHELATING AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHAREBY MANUFACTURER, 2008Table 36 : CORTICOSTEROIDS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHAREBY MANUFACTURER, 2008Table 37 : IMMUNOSUPPRESSIVE AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE:MARKET SHARE BY MANUFACTURER, 2008Table 38 : ANTIMETABOLITES TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BYMANUFACTURER, 2008Table 39 : ANABOLIC STEROIDS TO TREAT ALCOHOL-INDUCED LIVER DISEASE: MARKETSHARE BY MANUFACTURER, 2008Table 40 : ALCOHOL ABUSE DRUGS: MARKET SHARE BY MANUFACTURER, 2008Table 41 : ANTI-REJECTION MEDICATION TO TREAT CHRONIC LIVER DISEASE: MARKETSHARE BY MANUFACTURER, 2008Table 42 : ANTI-INFECTIVES TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BYMANUFACTURER, 2008Table 43 : ANTIFUNGAL PROPHYLAXIS TO TREAT CHRONIC LIVER DISEASE: MARKETSHARE BY MANUFACTURER, 2008Table 44 : GALLSTONE STABILIZING AGENTS: MARKET SHARE BY MANUFACTURER, 2008Table 45 : OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE:MARKET SHARE BY MANUFACTURER, 2008Table 46 : GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, BY DISEASE TYPE,
  • 7. THROUGH 2014Table 47 : GLOBAL SALES OF DRUGS TO TREAT HEPATITIS, THROUGH 2014Table 48 : GLOBAL SALES OF DRUGS TO TREAT LIVER TUMORS, THROUGH 2014Table 49 : GLOBAL SALES OF DRUGS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2014Table 50 : GLOBAL SALES OF DRUGS TO TREAT ALCOHOL-INDUCED LIVER DISEASES,THROUGH 2014Table 51 : GLOBAL SALES OF DRUGS TO TREAT CHRONIC LIVER DISEASES, THROUGH2014Table 52 : GLOBAL SALES OF DRUGS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES,THROUGH 2014Table 53 : DRUGS THAT CAN CAUSE LIVER DISEASETable 54 : NUMBER OF CLINICAL TRIALS FOR HEPATITIS/ LIVER-INDUCED LIVER DISEASESTable 55 : NUMBER OF CLINICAL TRIALS FOR LIVER TUMORSTable 56 : NUMBER OF CLINICAL TRIALS FOR CONGENITAL LIVER DEFECTSTable 57 : NUMBER OF CLINICAL TRIALS FOR AUTOIMMUNE LIVER DISORDERSTable 58 : NUMBER OF CLINICAL TRIALS FOR ALCOHOL-INDUCED LIVER DISEASESTable 59 : NUMBER OF CLINICAL TRIALS FOR CHRONIC LIVER DISEASESTable 60 : NUMBER OF CLINICAL TRIALS FOR NON-ALCOHOLIC FATTY LIVER DISEASETable 61 : GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, THROUGH 2014Table 62 : SHARE OF DRUGS TO TREAT LIVER DISEASES, 2008Table 63 : GLOBAL SALES OF HEPATITIS VACCINE, THROUGH 2014Table 64 : GLOBAL SALES OF NUCLEOSIDE ANALOGS TO TREAT LIVER DISEASES, BYREGION, THROUGH 2014Table 65 : GLOBAL SALES OF NUCLEOTIDE ANALOGS TO TREAT LIVER DISEASES, BYREGION, THROUGH 2014Table 66 : GLOBAL SALES OF INTERFERONS TO TREAT LIVER DISEASES, BY REGION,THROUGH 2014Table 67 : GLOBAL SALES OF IMMUNE GLOBULINS TO TREAT LIVER DISEASES, BY REGION,THROUGH 2014Table 68 : GLOBAL SALES OF CHEMOTHERAPY DRUGS TO TREAT LIVER DISEASES, BYREGION, THROUGH 2014Table 69 : GLOBAL SALES OF TARGETED THERAPY TO TREAT LIVER CANCER, BY REGION,THROUGH 2014Table 70 : GLOBAL SALES OF CHELATING AGENTS TO TREAT LIVER DISEASES, BY REGION,THROUGH 2014Table 71 : GLOBAL SALES OF CORTICOSTEROIDS TO TREAT LIVER DISEASES, BY REGION,THROUGH 2014Table 72 : GLOBAL SALES OF IMMUNOSUPPRESSIVE AGENTS TO TREAT LIVER DISEASES,BY REGION, THROUGH 2014Table 73 : GLOBAL SALES OF ANTIMETABOLITES TO TREAT LIVER DISEASES, BY REGION,THROUGH 2014Table 74 : GLOBAL SALES OF ANABOLIC STEROIDS TO TREAT LIVER DISEASES, BYREGION, THROUGH 2014Table 75 : GLOBAL SALES OF ALCOHOL ABUSE DRUGS BY REGION, 2007-2014Table 76 : GLOBAL SALES OF ANTI-REJECTION MEDICATION TO TREAT LIVER DISEASES,BY REGION, THROUGH 2014Table 77 : GLOBAL SALES OF INFECTION-FIGHTING DRUGS TO TREAT LIVER TRANSPLANTPATIENTS, BY REGION, THROUGH 2014Table 78 : GLOBAL SALES OF ANTIFUNGAL PROPHYLAXIS IN LIVER TRANSPLANTS, BY
  • 8. REGION, THROUGH 2014Table 79 : GLOBAL SALES OF GALLSTONE SOLUBILIZING AGENTS, BY REGION, THROUGH2014Table 80 : GLOBAL SALES OF OTHER DRUGS USED TO TREAT NON- ALCOHOLIC FATTYLIVER DISEASES, BY REGION, THROUGH 2014Table 81 : TOTAL NUMBER OF PATENTS EACH YEAR, 2005–2009Table 82 : NUMBER OF PATENTS BY TYPE, 2005–2009Table 83 : TOTAL NUMBER OF PATENTS BY COUNTRY, 2005–2009Table 84 : NUMBER OF PATENTS BY COMPANY, 2005–2009Table 85 : NUMBER OF PATENTS BY ASIGNEE, 2005–2009List of FiguresSummary Figure : GLOBAL SALES OF LIVER DISEASE TREATMENTS, 2007-2014Figure 1 : NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASES,2005–2008Figure 2 : HEPATITIS VACCINE: MARKET SHARE BY MANUFACTURER, 2008Figure 3 : NUCLEOSIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BYMANUFACTURER, 2008Figure 4 : NUCLEOTIDE ANALOGS TO TREAT HEPATITS: MARKET SHARE BYMANUFACTURER, 2008Figure 5 : INTERFERONS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008Figure 6 : IMMUNE GLOBULINS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER,2008Figure 7 : CHEMOTHERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER,2008Figure 8 : TARGETED THERAPY TO TREAT LIVER TUMORS: MARKET SHARE BYMANUFACTURER, 2008Figure 9 : CHELATING AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHAREBY MANUFACTURER, 2008Figure 10 : CORTICOSTEROIDS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHAREBY MANUFACTURER, 2008Figure 11 : IMMUNOSUPPRESSIVE AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE:MARKET SHARE BY MANUFACTURER, 2008Figure 12 : ANTIMETABOLITES TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHAREBY MANUFACTURER, 2008Figure 13 : ANABOLIC STEROIDS TO TREAT ALCOHOL-INDUCED LIVER DISEASE: MARKETSHARE BY MANUFACTURER, 2008Figure 14 : ALCOHOL ABUSE DRUGS: MARKET SHARE BY MANUFACTURER, 2008Figure 15 : ANTI-REJECTION MEDICATION TO TREAT CHRONIC LIVER DISEASE: MARKETSHARE BY MANUFACTURER, 2008Figure 16 : ANTI-INFECTIVES TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BYMANUFACTURER, 2008Figure 17 : ANTIFUNGAL PROPHYLAXIS TO TREAT CHRONIC LIVER DISEASE: MARKETSHARE BY MANUFACTURER, 2008Figure 18 : GALLSTONE STABILIZING AGENTS: MARKET SHARE BY MANUFACTURER, 2008Figure 19 : OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE:MARKET SHARE BY MANUFACTURER, 2008Figure 20 : GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, BY DISEASE TYPE,2007-2014
  • 9. Figure 21 : GLOBAL SALES OF DRUGS TO TREAT HEPATITIS, 2007-2014Figure 22 : GLOBAL SALES OF DRUGS TO TREAT LIVER TUMORS, 2007-2014Figure 23 : GLOBAL SALES OF DRUGS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2014Figure 24 : GLOBAL SALES OF DRUGS TO TREAT ALCOHOL-INDUCED LIVER DISEASES,2007-2014Figure 25 : GLOBAL SALES OF DRUGS TO TREAT CHRONIC LIVER DISEASES, 2007-2014Figure 26 : GLOBAL SALES OF DRUGS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES,2007-2094Figure 27 : GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, 2007-2014Figure 28 : SHARE OF DRUGS TO TREAT LIVER DISEASES, 2008Figure 29 : GLOBAL SALES OF HEPATITIS VACCINE, 2007-2014Figure 30 : GLOBAL SALES OF NUCLEOSIDE ANALOGS TO TREAT LIVER DISEASES, BYREGION, 2007-2014Figure 31 : GLOBAL SALES OF NUCLEOTIDE ANALOGS TO TREAT LIVER DISEASES, BYREGION, 2007-2014Figure 32 : GLOBAL SALES OF INTERFERONS TO TREAT LIVER DISEASES, BY REGION,2007-2014Figure 33 : GLOBAL SALES OF IMMUNE GLOBULINS TO TREAT LIVER DISEASES, BYREGION, 2007-2014Figure 34 : GLOBAL SALES OF CHEMOTHERAPY DRUGS TO TREAT LIVER DISEASES, BYREGION, 2007-2014Figure 35 : GLOBAL SALES OF TARGETED THERAPY TO TREAT LIVER CANCER, BY REGION,2007-2014Figure 36 : GLOBAL SALES OF CHELATING AGENTS TO TREAT LIVER DISEASES, BYREGION, 2007-2014Figure 37 : GLOBAL SALES OF CORTICOSTEROIDS TO TREAT LIVER DISEASES, BY REGION,2007-2014Figure 38 : GLOBAL SALES OF IMMUNOSUPPRESSIVE AGENTS TO TREAT LIVER DISEASES,BY REGION, 2007-2014Figure 39 : GLOBAL SALES OF ANTIMETABOLITES TO TREAT LIVER DISEASES, BY REGION,2007-2014Figure 40 : GLOBAL SALES OF ANABOLIC STEROIDS TO TREAT LIVER DISEASES, BYREGION, 2007-2014Figure 41 : GLOBAL SALES OF ALCOHOL ABUSE DRUGS, BY REGION, 2007-2014Figure 42 : GLOBAL SALES OF ANTI-REJECTION MEDICATION TO TREAT LIVER DISEASES,BY REGION, 2007-2014Figure 43 : GLOBAL SALES OF INFECTION-FIGHTING DRUGS TO TREAT LIVER TRANSPLANTPATIENTS, BY REGION, 2007-2014Figure 44 : GLOBAL SALES OF ANTIFUNGAL PROPHYLAXIS IN LIVER TRANSPLANTS, BYREGION, 2007-2014Figure 45 : GLOBAL SALES OF GALLSTONE SOLUBILIZING AGENTS, BY REGION, 2007-2014Figure 46 : GLOBAL SALES OF OTHER DRUGS USED IN THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASES, BY REGION, 2007-2014Figure 47 : TOTAL NUMBER OF PATENTS EACH YEAR, 2005–2009Figure 48 : NUMBER OF PATENTS BY TYPE, 2005–2009Figure 49 : PATENTS, SHARE BY TYPE, 2005–2009Figure 50 : TOTAL NUMBER OF PATENTS BY COUNTRY, 2005–2009Figure 51 : TOTAL NUMBER OF PATENTS BY COMPANY, 2005–2009Figure 52 : NUMBER OF PATENTS BY ASSIGNEE, 2005–2009
  • 10. Latest Market Research Reports: Merchant Hydrogen Generation and On-site Distributed Generation Global Markets for Flame Retardant Chemicals and Plastics The Global Catheters Market DNA Sequencing: Emerging Technologies and Applications 2011 Fuel Cell Industry Review 2011 Hybrid & Electric Vehicle Progree ReviewAbout Us:ReportsnReports is an online library of over 75,000 market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market researchreports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr. Priyank7557 Rambler road,Suite 727, Dallas, TX 75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit Our Market Research Reports Blog